PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health (PROMISE)
The PROMISE Study: PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Emily Jungheim, MD, MSCI
- Phone Number: 312-926-6643
- Email: Emily.Jungheim@nm.org
Study Contact Backup
- Name: Brianna Borger, BS
- Phone Number: 312-503-8208
- Email: Brianna.Borger1@nm.org
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern Medicine Fertility and Reproductive Medicine
-
Contact:
- Emily Jungheim, MD, MSCI
- Email: Emily.Jungheim@nm.org
-
Contact:
- Brianna Borger, BS
- Phone Number: 312-503-8208
- Email: Brianna.Borger1@nm.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Women ages 18-44 seeking pregnancy at Northwestern Fertility and Reproductive Medicine (FRM) who agree to
- Be followed for a period for up to 25 years
- Share information regarding their child's health
- No prior IVF cycles
Exclusion Criteria:
- Women using donor oocytes or gestational carriers
- Inability or unwillingness to provide informed consent for any aspects of the study
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Live birth after embryo transfer
Time Frame: ~0-24 months
|
Live birth after embryo transfer (y/n)
|
~0-24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cycle number
Time Frame: ~0-24 months
|
IVF cycle number
|
~0-24 months
|
|
AMH
Time Frame: ~0-24 months
|
Most recent AMH
|
~0-24 months
|
|
Antral follicle count (AFC)
Time Frame: ~0-24 months
|
Most recent AFC
|
~0-24 months
|
|
Diagnosis/reason for ART
Time Frame: ~0-24 months
|
E.g., male factor, DOR, tubal factor
|
~0-24 months
|
|
Stimulation type
Time Frame: ~0-24 months
|
Antagonist, microcode flare, long agonist, minimal stimulation
|
~0-24 months
|
|
Total gonadotropin dose (IU/L)
Time Frame: ~0-24 months
|
Total gonadotropin dose
|
~0-24 months
|
|
Maximum estradiol level (pmol/L)
Time Frame: ~0-24 months
|
Maximum estradiol level
|
~0-24 months
|
|
Days of stimulation
Time Frame: ~0-24 months
|
Total number of days of stimulation
|
~0-24 months
|
|
Trigger type
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Sperm source
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Number follicles >14 mm
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Cycle cancellation
Time Frame: ~0-24 months
|
Cycle cancellation (Y/N).
If Y, reason for cancellation
|
~0-24 months
|
|
Number of oocytes retrieved
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Number of mature oocytes
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Number of blastocysts
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Number of embryos transferred
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Day of embryo transfer
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Type of embryo transfer
Time Frame: ~0-24 months
|
Frozen or fresh embryo transfer
|
~0-24 months
|
|
Frozen embryo transfer protocol
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Luteal phase support
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Number of embryos cryopreserved
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Stage of embryo cryopreservation
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Grade of embryo transferred
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
PGT
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
PGT indication
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
PGT methodology
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Endometrial thickness
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Ovarian hyperstimulation syndrome
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Clinical outcome
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Insemination Type
Time Frame: ~0-24 months
|
ICSI, conventional, split
|
~0-24 months
|
|
Singleton pregnancy
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Multiple gestation
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Asthma
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Gestational diabetes
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Insulin
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Gestational hypertension/pre-eclampsia
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Abruption
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Placental disorders
Time Frame: ~12-36 months
|
Placenta accreta, Placenta previa, Placenta increta, Placenta percreta
|
~12-36 months
|
|
Intrauterine growth restriction
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Congenital malformation
Time Frame: ~12-36 months
|
Cleft palate, genetic defect, limb defect, cardiac defect, other
|
~12-36 months
|
|
Thyroid disease
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Heart disease
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Renal disease
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Polyhydramnios
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Lupus
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Clinical chorioamnionitis
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Prenatal genetic testing
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Type of prenatal genetic testing
Time Frame: ~12-36 months
|
NIPT, CVS, amniocentesis
|
~12-36 months
|
|
Maternal blood type
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Preconception COVID vaccination
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Pregnancy COVID vaccination
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Predelivery hospitalization
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Maternal weight at oocyte retrieval
Time Frame: ~12-36 months
|
Weight (lbs)
|
~12-36 months
|
|
Maternal height at oocyte retrieval
Time Frame: ~12-36 months
|
Height (inches)
|
~12-36 months
|
|
Number of mature oocytes inseminated
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Number of mature oocytes fertilized (2PN)
Time Frame: ~0-24 months
|
~0-24 months
|
|
|
Maternal weight at embryo transfer
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Maternal weight at last OB visit
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Maternal weight at 1 year postpartum
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Date of delivery
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Time of delivery
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Weight at delivery
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Mode of delivery
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Preterm birth
Time Frame: ~12-36 months
|
Birth <37 weeks
|
~12-36 months
|
|
Spontaneous preterm birth
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Presentation of spontaneous preterm birth (if applicable)
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Tocolytic medication during pregnancy
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Gestational age at delivery
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Presentation of term birth (if applicable)
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Magnesium sulfate administered
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Intrapartum antibiotics
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Length of hospital stay
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Head circumference
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Maternal mortality
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Infection
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Anesthetic complication
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Antepartum hemorrhage
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Postpartum hemorrhage
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Blood transfusion
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Thromboembolism
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Birthweight
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Small-for-gestational age
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Large-for-gestational age
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
1-min APGAR score
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
5-min APGAR score
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Arterial umbilical cord pH
Time Frame: ~12-36 months
|
~12-36 months
|
|
|
Breastfeeding compliance
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Postpartum weight change
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
General well-being
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Length of NICU stay
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Neonatal death
Time Frame: ~12-48 months
|
<28 days post delivery
|
~12-48 months
|
|
Breastfeeding
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Supplemental formula
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Breastfeeding at 1 year of life
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Child weight at 1 year of life
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
Child height at 1 year of life
Time Frame: ~12-48 months
|
~12-48 months
|
|
|
NICU admission
Time Frame: ~12-48 months
|
~12-48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Emily Jungheim, MD, MCSI, Division Chief of Reproductive Endocrinology and Infertility
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STU00215252
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.